Insider buying last 90 days
No open-market insider purchases were filed for VERA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every VERA insider filing, plotted on the chart in Gekko.Open VERA in Gekko
NASDAQ: VERA
Vera Therapeutics (VERA) Stock Analysis & Forecast
Oct 12 close
$27.72−2.16 (−7.2%)
Gekko Brief
AI summaryOct 12 closeVera Therapeutics shares closed at $27.72, down 7.2% on the day, extending a decline that has taken the stock well below both its 50-day average of $32.59 and its 200-day average of $38.39, with the shorter average itself below the longer one. The GekkoIndex sits at 66, placing the stock in the Accumulation zone. Price remains 36.6% below the Gekko Fair Value of $43.71.
Vera Therapeutics next reports earnings on 4 November 2026, 23 days away, placing the release inside the next 20-trading-day stretch. No insider, Congress or unusual options activity has been recorded in the respective 90-day and 30-day windows. Seasonal patterns over 5 years show the next 20 trading days averaging a 1.7% gain, though that figure was higher in only 2 of those years, a mixed signal alongside the approaching earnings report. Worth noting is the stock's typical 20-day price move of 12.7%, which bears watching given how close the earnings date falls within that span.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Vera Therapeutics price vs fair value
Close $27.72200-day averageGekko Fair Value $43.71
Vera Therapeutics quick facts
- Market cap
- $1.99B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$5.87
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.05
- Volume
- 1.40M avg 2.52M
- 1-year return
- −9.2%
- Typical daily move
- ±6.1%
- Typical 20-day move
- ±12.7%
- 50-day average
- $32.59
- 200-day average
- $38.39
- Next earnings
- Nov 4
- Shares outstanding
- 72.06M
Vera Therapeutics swing-trade checklist
Vera Therapeutics scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $27.72 is below the 50-day ($32.59) and 200-day ($38.39) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
66, Accumulation
Reading 66 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
36.6% below
Price is 36.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+1.7% on average
From this point in the calendar, the next 20 trading days averaged +1.7% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Vera Therapeutics stock chart and price history
Vera Therapeutics closed at $27.72 on Oct 12, 2026, −9.2% over the past year, inside a 52-week range of $23.05 to $56.05.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −20.9%
- 3 months
- −35.7%
- 6 months
- −36.6%
- 1 year
- −9.2%
The full VERA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open VERA in Gekko
Follow Vera Therapeutics through every session
Put VERA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track VERA in GekkoFree for 7 days. No credit card required.
About Vera Therapeutics
Vera Therapeutics works on medicines for serious immune-related conditions, with its efforts concentrated in the United States. Its main candidate, atacicept, is a fusion protein given by patients themselves through an under-the-skin injection, and it is being tested in a Phase IIb trial for immunoglobulin A nephropathy. The company is best known for this program as its lead area of focus.
Alongside atacicept, Vera Therapeutics is also developing MAU868, a monoclonal antibody now in Phase 2 testing aimed at treating BK viremia infections. As a clinical-stage company, it centers its activity on advancing these drug candidates through trials rather than on selling approved products.
The company was established in 2016 and is headquartered in Brisbane, California. It originally operated under the name Trucode Gene Repair, Inc. before adopting its current name in April 2020. Its shares are listed on the NASDAQ under the ticker VERA.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- veratx.com
Vera Therapeutics GekkoIndex: the smart money zone
Vera Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 66, in the Accumulation zone, up 0.9 points over five sessions.
66Accumulation
Up 0.9 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 51 | +11.2% | +18.0% | ||
| Accumulation (current zone) | 253 | −0.2% | +0.3% | ||
| Neutral | 320 | +0.1% | +2.0% | ||
| Distribution | 49 | +1.9% | −4.2% | ||
| Selling | 9 | Too few readings yet | |||
Average VERA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the VERA price, zone by zone.Track VERA in Gekko
Is Vera Therapeutics stock overvalued? Gekko Fair Value
Vera Therapeutics trades 36.6% below Gekko Fair Value of $43.71, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Vera Therapeutics shares are worth, recalculated every trading day.
$43.71
Gekko Fair Value, Oct 10, 2026
36.6% Undervalued
At the end of Aug 2026 the price was 45.7% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open VERA in Gekko
Vera Therapeutics insider and Congress trading
No open-market insider purchases were filed for Vera Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in VERA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for VERA, plotted on the chart in Gekko.Open VERA in Gekko
Buybacks
Vera Therapeutics has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2024
- $13K
- As a share of market cap
- 0.00%
From company filings.
Vera Therapeutics earnings: next date and track record
Vera Therapeutics reports on Nov 4, 2026 (23 days away), and beat the EPS estimate in 2 of its last 8 reports.
Next earnings report
Nov 4, 2026
23 days away
- EPS estimate
- −$1.61
- Revenue estimate
- $3.98M
2 of 8reports beat the EPS estimate
±4.8%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$1.52 est −$1.60 | — | −5.8% |
| May 7, 2026 | −$1.69 est −$1.33 | — est $426K | −1.1% |
| Feb 26, 2026 | −$1.39 est −$1.34 | — | −2.1% |
| Nov 5, 2025 | −$1.26 est −$1.20 | — | +3.6% |
| Aug 5, 2025 | −$1.20 est −$0.82 | — | −5.9% |
| May 6, 2025 | −$0.81 est −$0.75 | — | −11.4% |
| Feb 26, 2025 | −$0.72 est −$0.83 | — | +8.5% |
| Nov 7, 2024 | −$0.85 est −$0.64 | — | +0.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Vera Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Vera Therapeutics is $77.50, +179.6% from the last close, from 12 firms rating the stock in the last 90 days.
$77.50consensus 12-month target, +179.6% from the last close
Now $27.72Avg $77.50
Low $34High $100
Each firm’s latest rating in the last 90 days: 12 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | Leerink Partners | $34 | +22.7% |
| Oct 9 | Bank of America Securities | $60 | +116.5% |
| Oct 1 | H.C. Wainwright | $90 | +224.7% |
| Sep 16 | Wedbush | $34 | +22.7% |
| Sep 16 | Jefferies | $59 | +112.8% |
+0.3%average 20-day move after past Accumulation readings
+1.7%average move over the next 20 trading days in the last 5 years
±6.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Vera Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Vera Therapeutics averaged +1.7% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.7% | 3 of 5 |
| Next 10 trading days | −3.4% | 2 of 5 |
| Next 15 trading days | −2.2% | 2 of 5 |
| Next 20 trading days | +1.7% | 2 of 5 |
| Next 30 trading days | +14.4% | 3 of 5 |
For scale, VERA’s typical 20-trading-day move in either direction is about 12.7%.
Vera Therapeutics market cap and key statistics
Vera Therapeutics’s market cap is $1.99B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $1.99B
- EPS, TTM
- −$5.87
- Gekko Fair Value
- $43.71
Trading
- Volume
- 1.40M
- Avg volume, 20 days
- 2.52M
- 52-week high
- $56.05
- 52-week low
- $23.05
- Shares outstanding
- 72.06M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -91.7%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.05
- Typical daily move
- ±6.1%
- Typical 20-day move
- ±12.7%
Vera Therapeutics peers
Vera Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Vera Therapeutics stock FAQ
What is Vera Therapeutics’s market cap?
Vera Therapeutics’s market cap is $1.99B at the Oct 12, 2026 close of $27.72, with 72.06M shares outstanding.
What is the Vera Therapeutics stock forecast?
The consensus analyst 12-month price target for Vera Therapeutics is $77.50, +179.6% from the last close. Of the 12 firms that rated the stock in the last 90 days, 10 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Vera Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Vera Therapeutics is undervalued: the Oct 12, 2026 close of $27.72 is 36.6% below Gekko Fair Value of $43.71. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Vera Therapeutics report earnings next?
Vera Therapeutics is expected to report on Nov 4, 2026 (23 days away). Analysts expect earnings of −$1.61 per share on revenue of $3.98M. Vera Therapeutics beat the earnings estimate in 2 of its last 8 reports, moving 4.8% on average across the report.
What is Vera Therapeutics’s 52-week high and low?
Vera Therapeutics’s 52-week high is $56.05 and its 52-week low is $23.05; it closed at $27.72 on Oct 12, 2026, −9.2% over the past year.
Is Vera Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value), 1 as mixed (seasonality) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Vera Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.